Molecular mechanisms of IGF-I deficiency

Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The eight defects described above provide a foundation for the molecular diagnosis of Primary IGFD. Although each of these, in its classic form, appears rare, each defect serves to underscore the critical role of IGF-I in both intrauterine and postnatal growth. The major clinical and biochemical features of each condition are summarized in table 2 . With the exception of bioinactive IGF-I, they are all characterized by low serum concentrations of IGF-I, which fail to rise normally in response to exogenous GH administration. In the case of bioinactive IGF-I, serum concentrations of IGF-I, as measured by conventional radioassays, may be normal or even elevated, but bioassays reveal the underlying abnormality. It seems reasonable to speculate that these 'classic' forms of IGFD represent the tip of the iceberg, and that our understanding of less severe IGFD cases will expand over ensuing years. In addition to the established molecular defects described above, future areas of investigation for molecular etiologies of IGFD might include defects of JAK2, IGFBP-3, and various proteases and phosphatases that might impact GH signal transduction. Since studies suggest that as many as 25-50% of children labeled as 'idiopathic short stature' have reduced serum concentrations of IGF-I in the face of normal or elevated GH, such cases will warrant careful biochemical and molecular investigations, in an effort to identify more subtle defects of the GHR, GH signaling cascade or IGF-I gene expression.

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalHormone Research
Volume65
Issue numberSUPPL. 1
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor I
Serum
Phosphoric Monoester Hydrolases
Biological Assay
Signal Transduction
Gene Expression
Growth

ASJC Scopus subject areas

  • Endocrinology

Cite this

Molecular mechanisms of IGF-I deficiency. / Rosenfeld, Ronald (Ron).

In: Hormone Research, Vol. 65, No. SUPPL. 1, 02.2006, p. 15-20.

Research output: Contribution to journalArticle

Rosenfeld, RR 2006, 'Molecular mechanisms of IGF-I deficiency', Hormone Research, vol. 65, no. SUPPL. 1, pp. 15-20. https://doi.org/10.1159/000090642
Rosenfeld, Ronald (Ron). / Molecular mechanisms of IGF-I deficiency. In: Hormone Research. 2006 ; Vol. 65, No. SUPPL. 1. pp. 15-20.
@article{63bcdb6def3a4832bab13e4c71b9d650,
title = "Molecular mechanisms of IGF-I deficiency",
abstract = "The eight defects described above provide a foundation for the molecular diagnosis of Primary IGFD. Although each of these, in its classic form, appears rare, each defect serves to underscore the critical role of IGF-I in both intrauterine and postnatal growth. The major clinical and biochemical features of each condition are summarized in table 2 . With the exception of bioinactive IGF-I, they are all characterized by low serum concentrations of IGF-I, which fail to rise normally in response to exogenous GH administration. In the case of bioinactive IGF-I, serum concentrations of IGF-I, as measured by conventional radioassays, may be normal or even elevated, but bioassays reveal the underlying abnormality. It seems reasonable to speculate that these 'classic' forms of IGFD represent the tip of the iceberg, and that our understanding of less severe IGFD cases will expand over ensuing years. In addition to the established molecular defects described above, future areas of investigation for molecular etiologies of IGFD might include defects of JAK2, IGFBP-3, and various proteases and phosphatases that might impact GH signal transduction. Since studies suggest that as many as 25-50{\%} of children labeled as 'idiopathic short stature' have reduced serum concentrations of IGF-I in the face of normal or elevated GH, such cases will warrant careful biochemical and molecular investigations, in an effort to identify more subtle defects of the GHR, GH signaling cascade or IGF-I gene expression.",
author = "Rosenfeld, {Ronald (Ron)}",
year = "2006",
month = "2",
doi = "10.1159/000090642",
language = "English (US)",
volume = "65",
pages = "15--20",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Molecular mechanisms of IGF-I deficiency

AU - Rosenfeld, Ronald (Ron)

PY - 2006/2

Y1 - 2006/2

N2 - The eight defects described above provide a foundation for the molecular diagnosis of Primary IGFD. Although each of these, in its classic form, appears rare, each defect serves to underscore the critical role of IGF-I in both intrauterine and postnatal growth. The major clinical and biochemical features of each condition are summarized in table 2 . With the exception of bioinactive IGF-I, they are all characterized by low serum concentrations of IGF-I, which fail to rise normally in response to exogenous GH administration. In the case of bioinactive IGF-I, serum concentrations of IGF-I, as measured by conventional radioassays, may be normal or even elevated, but bioassays reveal the underlying abnormality. It seems reasonable to speculate that these 'classic' forms of IGFD represent the tip of the iceberg, and that our understanding of less severe IGFD cases will expand over ensuing years. In addition to the established molecular defects described above, future areas of investigation for molecular etiologies of IGFD might include defects of JAK2, IGFBP-3, and various proteases and phosphatases that might impact GH signal transduction. Since studies suggest that as many as 25-50% of children labeled as 'idiopathic short stature' have reduced serum concentrations of IGF-I in the face of normal or elevated GH, such cases will warrant careful biochemical and molecular investigations, in an effort to identify more subtle defects of the GHR, GH signaling cascade or IGF-I gene expression.

AB - The eight defects described above provide a foundation for the molecular diagnosis of Primary IGFD. Although each of these, in its classic form, appears rare, each defect serves to underscore the critical role of IGF-I in both intrauterine and postnatal growth. The major clinical and biochemical features of each condition are summarized in table 2 . With the exception of bioinactive IGF-I, they are all characterized by low serum concentrations of IGF-I, which fail to rise normally in response to exogenous GH administration. In the case of bioinactive IGF-I, serum concentrations of IGF-I, as measured by conventional radioassays, may be normal or even elevated, but bioassays reveal the underlying abnormality. It seems reasonable to speculate that these 'classic' forms of IGFD represent the tip of the iceberg, and that our understanding of less severe IGFD cases will expand over ensuing years. In addition to the established molecular defects described above, future areas of investigation for molecular etiologies of IGFD might include defects of JAK2, IGFBP-3, and various proteases and phosphatases that might impact GH signal transduction. Since studies suggest that as many as 25-50% of children labeled as 'idiopathic short stature' have reduced serum concentrations of IGF-I in the face of normal or elevated GH, such cases will warrant careful biochemical and molecular investigations, in an effort to identify more subtle defects of the GHR, GH signaling cascade or IGF-I gene expression.

UR - http://www.scopus.com/inward/record.url?scp=33644615196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644615196&partnerID=8YFLogxK

U2 - 10.1159/000090642

DO - 10.1159/000090642

M3 - Article

C2 - 16508329

AN - SCOPUS:33644615196

VL - 65

SP - 15

EP - 20

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - SUPPL. 1

ER -